Authors
Latest:
Emerging Biopharma Tackles the Opioid CrisisDr. Steven Fox, CEO of Akelos Inc., discusses the challenges of developing new non-opioid medical products as the need intensifies as the crisis worsens.
Latest:
Pricing Climate Heats Up in US and EuropeIn 2003, Big Pharma produced only a dozen new drugs. At the same time, it came under new pressure to create value from those thin pipelines. In that "hot squeeze" of a climate, pharma companies needed price premiums for every product in every market. They were more successful in some countries than in others. Other pricing trends also took their toll.
Latest:
Halting the HypeUnfortunately, companies sometimes violate the public trust by issuing false or misleading statements about FDA-related issues, such as the progress of FDA's pre-market review. When we identify suspected misstatements, we have a new process to bring them to the attention of the SEC staff as quickly and efficiently as possible." Then FDA Commissioner Mark McClellan issued that statement in a February press release.
Latest:
Transforming Drug Safety Through Innovation - Q&A with Vikram AnandEVERSANA’s president of compliance services discusses the launch of EVERSANA ORCHESTRATE PV.
Latest:
Inside DDMAC: A Conversation with Thomas AbramsDespite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says Tom Abrams, director of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). Abrams has been on all sides of drug marketing, from receiving promotions as a pharmacist to creating promotions as a member of industry to regulating promotions as the head of DDMAC. As such, he's in good position to see the big picture.
Latest:
Optimal Pricing StrategiesPricing has never been more of a key issue for the industry than it is right now. Yet, even with the increased importance of pricing strategies, a lack of focus on critical market factors leads many manufacturers to forego profits or increase their vulnerability to aggressive payers. Aligning pricing and contracting can achieve a sustainable competitive advantage-if product managers objectively assess a product's clinical benefits and address two key questions:
Latest:
Data Unleashed: Cooperation Among CompetitorsCharting two years of collaborative progress in clinical trial data sharing.
Latest:
Paying for the Future of MedicineThe three leading justifications for sticker-shocking drug prices in the US.
Latest:
A New Game Plan for Pharma HRNew dynamics are forcing the industry's human resource departments to rethink their operational game plans. The drivers-consolidation, globalization, scientific advances, public policy, and competition-have pushed HR leaders into new territory to address business needs.
Latest:
Dangerous Liaisons: Terrorism and PharmaHow vulnerable is Big Pharma to the predations of organized terrorist groups or that rogue malcontent with an agenda to wreak havoc on society?
Latest:
Specialty Service Programs: Gearing up for Next Generation TechnologiesInnovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space.
Latest:
Innovation Calls Across the C-suite: Lessons From Wall StreetThe lifeblood of the life sciences industry is continuous innovation-it is not a business that can survive by standing still.
Latest:
The JOBS Act: A Boost for Biopharma?Amid one of the most divisive eras in our nation’s political history, one thing we can all pretty much agree on is the fact that our stalled economic engine needs a jumpstart.
Latest:
Measuring the ROI of SPP Adherence ProgramsCan deeper data from specialty pharmacy providers bolster both patient outcomes and financial returns?
Latest:
Rare Disease Week: Progress, But Still Very Few TreatmentsSteve Smith provides an advocates account of last month's Rare Disease Week on Capitol Hill.
Latest:
Dangerous Liaisons: Terrorism and PharmaHow vulnerable is Big Pharma to the predations of organized terrorist groups or that rogue malcontent with an agenda to wreak havoc on society?
Latest:
Early Engagement with Medical LaboratoriesTimely engagement is the key to expanding the use of companion diagnostics.
Latest:
Marriages Made in Heaven?In recent years, some of the industry's largest companies have said "I do" at the merger altar. Midsized pharma, small biotech, and genomics companies have also joined the mating frenzy. The mixed results of those unions have left shareholders, customers, and employees wondering-are such marriages made in heaven or in hell?
Latest:
The keys to territory & time managementGood territory and time management is the foundation of all successful selling, and successful territory and time management involves thorough knowledge of your territory.
